AU6740298A - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- AU6740298A AU6740298A AU67402/98A AU6740298A AU6740298A AU 6740298 A AU6740298 A AU 6740298A AU 67402/98 A AU67402/98 A AU 67402/98A AU 6740298 A AU6740298 A AU 6740298A AU 6740298 A AU6740298 A AU 6740298A
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9706089 | 1997-03-24 | ||
GBGB9706089.1A GB9706089D0 (en) | 1997-03-24 | 1997-03-24 | Pharmaceutical composition |
PCT/GB1998/000885 WO1998042344A1 (en) | 1997-03-24 | 1998-03-24 | Pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6740298A true AU6740298A (en) | 1998-10-20 |
Family
ID=10809779
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU67402/98A Abandoned AU6740298A (en) | 1997-03-24 | 1998-03-24 | Pharmaceutical composition |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0969842A1 (en) |
JP (1) | JP2001518925A (en) |
AU (1) | AU6740298A (en) |
GB (1) | GB9706089D0 (en) |
WO (1) | WO1998042344A1 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9904911D0 (en) * | 1999-03-03 | 1999-04-28 | Scherer Ltd R P | Pharmaceutical compositions |
US6268368B1 (en) * | 2000-03-01 | 2001-07-31 | American Pharmaceuticals International | Anionic exchange polymer complexes of buspirone |
EP1256343B1 (en) * | 2001-05-11 | 2006-07-05 | Jürgen K. Dr. Beck | Flibanserin for the treatment of extrapyramidal movement disorders |
US8106074B2 (en) | 2001-07-13 | 2012-01-31 | Pierre Fabre Medicament | Pyridin-2-yl-methylamine derivatives for treating opiate dependence |
JP5080716B2 (en) * | 2001-07-20 | 2012-11-21 | サイコジェニックス・インコーポレーテッド | Treatment of attention deficit / hyperactivity disorder |
US7183410B2 (en) | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
DE10138273A1 (en) * | 2001-08-10 | 2003-02-27 | Boehringer Ingelheim Pharma | Medicines with neuroprotective effects |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
GB0129117D0 (en) * | 2001-12-05 | 2002-01-23 | Glaxo Group Ltd | Pharmaceutical composition |
US20040002500A1 (en) * | 2002-06-28 | 2004-01-01 | Fabre Kramer Pharmaceutical, Inc. | Methods for treating attention deficit disorder |
WO2004069339A1 (en) * | 2003-01-29 | 2004-08-19 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
JP2007510629A (en) * | 2003-10-22 | 2007-04-26 | イーライ リリー アンド カンパニー | Novel MCH receptor antagonist |
AR049478A1 (en) | 2004-03-25 | 2006-08-09 | Solvay Pharm Bv | A PROCEDURE FOR THE PREPARATION OF 3-AMINO-8- (1-PIPERAZINIL) -2H-1-BENZOPIRAN-2-ONA. SALTS AND HYDRATES AND PHARMACEUTICAL COMPOSITIONS. |
WO2006005760A1 (en) * | 2004-07-15 | 2006-01-19 | Solvay Pharmaceuticals B.V. | Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one |
WO2006024471A1 (en) * | 2004-09-03 | 2006-03-09 | Boehringer Ingelheim International Gmbh | Method for the treatment of attention deficit hyperactivity disorder |
JP2008540356A (en) * | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Drug abuse treatment methods |
US20060258640A1 (en) * | 2005-05-13 | 2006-11-16 | Boehringer Ingelheim International Gmbh | Use of Flibanserin in the treatment of chronic pain |
WO2007014929A1 (en) | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Use of flibanserin in the treatment of obesity |
WO2007048803A1 (en) | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
CA2641917A1 (en) * | 2006-02-18 | 2007-08-23 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin |
EP1988897A1 (en) * | 2006-02-20 | 2008-11-12 | Boehringer Ingelheim International GmbH | Benzimidazolone derivatives for the treatment of urinary incontinence |
US9066903B2 (en) | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
JP2009536667A (en) * | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | 5HT receptor-mediated neurogenesis |
WO2008000760A1 (en) | 2006-06-30 | 2008-01-03 | Boehringer Ingelheim International Gmbh | Flibanserin for the treatment of urinary incontinence and related diseases |
EP2054041A2 (en) | 2006-08-14 | 2009-05-06 | Boehringer Ingelheim International GmbH | Formulations of flibanserin and method for manufacturing the same |
CN101505736A (en) | 2006-08-25 | 2009-08-12 | 贝林格尔.英格海姆国际有限公司 | Controlled release system and method for manufacturing the same |
CN1915233B (en) * | 2006-08-30 | 2012-10-03 | 四川科瑞德制药有限公司 | Medicine composition for treating anxiety neurosis, and oral cavity disintegration preparation |
PE20091188A1 (en) | 2007-09-12 | 2009-08-31 | Boehringer Ingelheim Int | COMPOUND 1- [2- (4- (3-TRIFLUOROMETIL-PHENYL) PIPERAZIN-1-IL) ETHYL] -2,3-DIHYDRO-1H-BENZIMIDAZOL-2-ONA (FLIBANSERIN), ITS ADDITION SALTS AND PHARMACEUTICAL COMPOSITIONS THAT THEY CONTAIN |
KR101825972B1 (en) * | 2010-10-15 | 2018-02-06 | 콘테라 파르마 에이피에스 | Combinations of serotonin receptor agonists for treatment of movement disorders |
CN113880815B (en) * | 2020-07-03 | 2024-03-29 | 中国药科大学 | Indole derivatives, preparation method and application thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1548022A (en) * | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
US5288498A (en) * | 1985-05-01 | 1994-02-22 | University Of Utah Research Foundation | Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
US4634703A (en) * | 1985-10-25 | 1987-01-06 | Bristol-Myers Company | Method for alleviation of panic disorders |
US4687772A (en) * | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
JPS63250318A (en) * | 1987-04-06 | 1988-10-18 | Fujimoto Seiyaku Kk | Pharmaceutical preparation suitable in oral cavity |
SE8704097D0 (en) * | 1987-10-22 | 1987-10-22 | Astra Ab | ORAL FORMULATION OF BUSPIRONE AND SALTS THEREOF |
GB8819024D0 (en) * | 1988-08-10 | 1988-09-14 | Glaxo Group Ltd | Chemical compounds |
SK281621B6 (en) * | 1990-06-07 | 2001-05-10 | Astrazeneca Ab | Therapeutic heterocyclic compounds |
US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
JPH04360826A (en) * | 1991-06-07 | 1992-12-14 | Bayer Yakuhin Kk | Controlled release pharmaceutical preparation |
US5169638A (en) * | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
DE69222006T2 (en) * | 1991-10-30 | 1998-01-22 | Glaxo Group Ltd | Multilayer compositions containing histamine or serotonin antagonists |
US5246710A (en) * | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating cyclothymia |
US5246711A (en) * | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating dysthymia |
GB9226530D0 (en) * | 1992-12-21 | 1993-02-17 | Smithkline Beecham Plc | Compounds |
AP486A (en) * | 1993-04-27 | 1996-04-16 | Pfizer | Indole derivatives. |
DE4319760A1 (en) * | 1993-06-15 | 1994-12-22 | Bayer Ag | Ipsapiron drug preparation |
GB9417310D0 (en) * | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
US5478572A (en) * | 1994-09-06 | 1995-12-26 | Bristol-Myers Squibb Co. | Gepirone dosage form |
US5698571A (en) * | 1994-10-05 | 1997-12-16 | Eli Lilly And Company | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
ES2151993T3 (en) * | 1995-06-23 | 2001-01-16 | Lilly Co Eli | 1,2,3,4-TETRAHIDRO-9H-CARBAZOLES 6-SUBSTITUTES AND 10H-CICLOHEPTA (7,6-B) INDOLES 7-SUBSTITUTES. |
CA2259418A1 (en) * | 1996-07-11 | 1998-01-22 | Farmarc Nederland B.V. | Pharmaceutical composition containing acid addition salt of basic drug |
-
1997
- 1997-03-24 GB GBGB9706089.1A patent/GB9706089D0/en active Pending
-
1998
- 1998-03-24 EP EP98912622A patent/EP0969842A1/en not_active Withdrawn
- 1998-03-24 JP JP54523598A patent/JP2001518925A/en not_active Ceased
- 1998-03-24 AU AU67402/98A patent/AU6740298A/en not_active Abandoned
- 1998-03-24 WO PCT/GB1998/000885 patent/WO1998042344A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
GB9706089D0 (en) | 1997-05-14 |
JP2001518925A (en) | 2001-10-16 |
EP0969842A1 (en) | 2000-01-12 |
WO1998042344A1 (en) | 1998-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6740298A (en) | Pharmaceutical composition | |
AU4762797A (en) | Pharmaceutical compositions | |
AU2967597A (en) | Pharmaceutical compositions | |
AU5387898A (en) | Pharmaceutical agents | |
AU8107998A (en) | Pharmaceutical compositions | |
AU3777897A (en) | Pharmaceutical compositions | |
AU5335798A (en) | Stomatic composition | |
AU5317598A (en) | Novel pharmaceutical compositions | |
AU8591898A (en) | Pharmaceutical compounds | |
AU8747498A (en) | Food-preservative composition | |
AU7904998A (en) | Pharmaceutical composition containing peptichemio | |
GB9717444D0 (en) | Pharmaceutical composition | |
AU2531295A (en) | Pharmaceutical composition | |
HUP0002455A3 (en) | Gastric-retained pharmaceutical composition | |
AU9343098A (en) | Pharmaceutical composition | |
AU8121998A (en) | Composition | |
AUPP332898A0 (en) | Pharmaceutical composition | |
AU1098499A (en) | Emulsifier-lipid composition | |
AU4326197A (en) | Pharmaceutical compositions | |
AU4457597A (en) | Pharmaceutical compositions | |
AUPN862596A0 (en) | Pharmaceutical compositions | |
GB9717770D0 (en) | Pharmaceutical composition | |
GB2321190B (en) | Pharmaceutical composition | |
GB9726781D0 (en) | Pharmaceutical composition | |
AUPO598497A0 (en) | Pharmaceutical composition |